Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Ten new products in Paragraph IV to be launched by TEVA |
 |
 |
 |
|
Teva Pharma Has Plans to Launch About 25 Drugs by Year's End
Teva Pharmaceutical Industries plans to try to launch about 25 generic products in the next five months whose brand counterparts have an estimated $23 billion in annual sales. About 10 of the planned launches include active Paragraph IV challenges, Shlomo Yanai, Teva's president and CEO, says in a statement on the company's second-quarter earnings. Teva has about 198 ANDAs pending with the FDA, including 42 tentative approvals. The brand products covered by these applications have annual U.S. sales of over $110 billion, according to a company statement |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis